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Abstract 
Background: India has a large number of HIV infected patients being followed up at anti-retroviral therapy (ART) 
centers. The patients are regularly offered CD4 count estimation for deciding their eligibility for ART initiation as well 
as for monitoring response to ART, making CD4 count estimation a very critical test. Hence, quality control of CD4 
testing is utmost important for ultimate success of ART program. As the commercial controls are very expensive, 
internal quality control (IQC), at present, is being done by duplicate analysis method using previous day samples in 
most of the laboratories. Hence the study was undertaken to review performance of duplicate analysis method for 
monitoring daily IQC.
Methods: Quality control (QC) data from 11 Indian laboratories using duplicate analysis and/or commercial controls 
for IQC of CD4 testing was collected for reviewing information on QC parameters such as precision, accuracy and 
trend monitoring. Precision was determined by r2 values and mean % variation for duplicate analysis and coefficient 
of variation (% CV) for commercial controls. Accuracy was monitored by rate of QC failures for both the types of con-
trol and trend monitoring was done by plotting LJ charts for commercial controls and by plotting daily % variation for 
duplicate analysis.
Results: The laboratories using duplicate analysis for IQC showed good precision with mean % variation ranging 
from 0.5 to 7.2. There was good match between r2 values and % CV of the laboratories performing both the types of 
QC methods. Rates of QC failures were 2.3 for duplicate analysis and 3 per laboratory-year for IMMUNO-TROL controls. 
Daily trend monitoring showed fluctuation of daily counts around mean in LJ charts and of percent variation around 
0% in duplicate analysis method. Commercially available controls showed limitations such as altered specimen quality 
leading to difficulties in manual gating and issues with the establishment of laboratory range.
Conclusion: Duplicate analysis can serve as a cheaper alternative to commercially available controls for IQC of CD4 
testing especially when supplemented with other QC measures for controlling variations caused by reagent, equip-
ment, staff and environment in addition to the successful participation in External Quality Assurance programme.
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Background
India has been successful in controlling epidemic of 
the Human Immunodeficiency Virus (HIV) as evident 
from reduction of adult prevalence from 0.41% in 2001 
to 0.27% in 2011 with the current estimated number of 
people living with HIV/AIDS (PLHIV) being 2.089 mil-
lion [1]. Additionally, free ART (anti-retroviral therapy) 
program in India has improved quality of life of people 
living with HIV/AIDS and has resulted in 29% reduction 
in estimated annual deaths due to AIDS related causes 
Open Access
*Correspondence:  mthakar@icmr.org.in 
National AIDS Research Institute, 73 G Block MIDC Bhosari, Pune 411026, 
India
Page 2 of 9Shete et al. AIDS Res Ther  (2015) 12:25 
between 2007 and 2012 [1]. As of March 2014, nearly 
1.76 million PLHIV have been registered at 425 ART cen-
tres of whom over 0.77 million clinically eligible patients 
are receiving free ART in Government health facilities 
[1]. For taking decision on initiation of ART and also for 
monitoring response to ART in HIV infected patients, 
currently CD4 lymphocyte enumeration is the only pri-
mary laboratory test used in India. Hence reliability of 
CD4 count report is very important for effectiveness 
of ART program. CD4 count estimation is performed 
at around 254 CD4 estimating laboratories and during 
2013-14 alone about 15,01,150 CD4 tests were performed 
[1]. Quality assurance programme for assuring reliability 
of CD4 counts for all these laboratories is monitored by 
National AIDS Research Institute (NARI) and National 
AIDS Control Organization (NACO) through staff train-
ings, external quality assessment programme, equipment 
maintenance, kit supplies, etc. Additionally the laborato-
ries also follow internal quality control procedures laid 
down in their own laboratories.
The main objective of internal quality control (IQC) 
is to ensure day-to-day consistency of an analytical pro-
cess [2, 3]. Hence, the focus of IQC is principally on 
monitoring precision and, to a lesser degree, on accu-
racy [4]. Under ideal conditions, IQC for CD4 count 
measurement is done using commercially available sta-
bilized blood samples [5] serving as Certified Reference 
Materials (CRMs) which are matrix-matched and have 
assigned target values and ranges for each variable, reli-
ably determined from data obtained by repeated analysis 
[5, 6]. They usually have open shelf life of 1–3  months 
[5]. Commercially available stabilized blood samples are 
recommended for daily QC for CD4 testing as they give 
information regarding precision, biases and accuracy 
of the results. Alternative method for QC is duplicate 
analysis method in which patient samples tested on pre-
vious day are used as QC material [7]. This method has 
two distinct advantages as the QC materials match with 
the exact nature of the sample (fresh whole blood), and 
the materials are readily available at any laboratory at no 
extra cost [6].
The major drawback of commercially available con-
trols is their cost which causes considerable stress on the 
management system in financial as well as logistic terms 
especially in settings where the CD4 count is being esti-
mated at such a large scale. Additionally India is moving 
towards decentralization of HIV treatment services to 
primary health care (PHC) centers to reduce the burden 
of providing HIV services on many tertiary care centres 
and also to enhance access to treatment like in many 
other countries. It may not be feasible to implement qual-
ity control using commercially available controls at PHC 
level as it would increase the budget by many folds in 
addition to issues related to their regular supply, trans-
port and storage conditions, compatibility with point of 
care machines, etc. In India, most of the CD4 laborato-
ries use duplicate analysis method (using previous day’s 
sample as IQC material), while only some laboratories 
use the commercial controls for QC monitoring. Hence 
in the present study, the performance of duplicate analy-
sis method in monitoring QC was reviewed in compari-
son to that of the commercial control in order to choose 
a cheaper QC method without compromising the qual-
ity. The IQC data from different laboratories in India 
using either or both the IQC methods was analyzed for 
parameters of IQC such as precision, accuracy and trend 
monitoring. The laboratories were selected for getting 
representative data from different equipments as well as 
from different geographic locations.
Results and discussion
Equipment displays of the processed samples and analysis
Displays of commercially stabilized blood samples were 
found to have poor separation of cell populations as 
compared to fresh blood samples as shown in Fig.  1. 
The stabilized blood samples have been shown to have 
altered light scatter and fluorescence staining properties 
as compared to fresh blood specimens, not satisfying the 
automatic gating algorithm defined by the instrument 
software [8, 9]. Hence manual gating was required in 
case of FACSCalibur for analysis of stabilized blood sam-
ples. Setting of manual gates was found to be challeng-
ing because of poor separation of populations, requiring 
intense training of the staff. Such gating was also found 
to be subjective and unreliable at many times by other 
investigators also [9]. FACSCount also sometimes failed 
to acquire these controls, especially IMMUNO-TROL 
controls, by giving a message of ‘Major tube failure’. Such 
testing failure due to inability to identify and gate clus-
ters of cells of interest in case of fully automated plat-
forms like FACSCount has also been reported in one of 
the studies [9]. Interestingly, the displays on Cyflow did 
not have much problem of poor separation as shown in 
Fig. 1.
Precision monitoring
The main objective of IQC is the monitoring of preci-
sion [4]. For commercially available controls, precision is 
determined by calculating % CV. The % CV for the com-
mercial controls ranged from 2.2 to 12.5 (Table 1) for dif-
ferent laboratories. In case of duplicate analysis method, 
% variation was used for monitoring daily precision. The 
mean % variation for different laboratories ranged from 
0.5 to 7.2 (Table  1). This was well within the accept-
able limit mentioned in the NACO and other guidelines. 
Long term precision in case of the duplicate analyses 
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Fig. 1 Representative displays of fresh and stabilized blood samples on FACSCount, FACSCalibur and Cyflow. Equipment displays in row 1 are for 
fresh blood sample used in duplicate analysis method, row 2 are for the multi-check stabilized blood sample and row 3 are for IMMUNO-TROL con-
trols. a, d, g are from FASCount; b, e, h from FACSCalibur and c, f, i from Cyflow. BD FACSCount CD4/CD3 reagent kit contained anti CD3 PE-Cy5 and 
anti CD4 PE antibodies. Tricolour reagent used for FACSCalibur analysis contained anti CD45 PerCP, anti CD3 FITC and anti CD4 PE antibodies. The 
gates shown in the figure are autogates set by the Multiset software used for FACSCalibur analysis. CD4 easy count kit used for Cyflow contained 
anti CD4 PE antibody for staining, where the gates were set manually.
Table 1 IQC details of CD4 testing laboratories
Laboratories Instrument used Mean (range of % variation  
for duplicate analysis)
Mean (range % CV for commercially 
available controls)
Laboratory 1 FACSCount 2.43, 0.6–3.3 3.9, 2.7–4.9 (IMMUNO-TROL)
Laboratory 2 FACSCount 7.2, 5.5–12.0 5.4, 3.4–7.0 (multi-check)
Laboratory 3 FACSCalibur 5.7, 2.5–7.2 12.4, 12.0–12.8 (multi-check)
Laboratory 4 FACSCalibur 5.1, 4.2–5.8 –
Laboratory 5 FACSCalibur 4.4, 2.6–6.4 2.2, 1.6–2.6 (multi-check)
Laboratory 6 FACSCalibur 5.9, 4.2–7.0 3.4, 3.0–3.8 (multi-check)
Laboratory 7 FACSCount 2.6, 2.1–3.5 3.5 (multi-check)
Laboratory 8 Cyflow 2.9, 2.0–3.9 –
Laboratory 9 Cyflow 0.5, 0.3–1.2 –
Laboratory 10 Cyflow 3.5, 1.6–5.6 –
Laboratory 11 FACSCalibur 4.8, 3.5–5.3 –
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was determined by calculating r2 values and mean of % 
variation over a period of time. All the laboratories using 
previous day sample as IQC showed good long term pre-
cision as evident from r2 value of more than 0.8 when 
data over 3 months was compared (Fig. 2). Bland–Altman 
analyses also demonstrated close agreement between day 
1 and day 2 CD4 counts, with biases of 8.28 ± 51.4 and 
2.38 ± 16.1, for the normal and low level absolute CD4 
count controls, respectively (Fig.  3). Where the parallel 
data on both the controls was available during the same 
time (N = 6 laboratories), the r2 values were found to fol-
low the same trend as the % CVs of commercial controls 
for the respective laboratories (Fig.  4). The laboratories 
showing lower % CV values also showed higher r2 values 
and vice a versa showing that the precision of duplicate 
analysis was comparable to that obtained using com-
mercially available controls. Thus, r2 values should also 
be calculated for duplicate analysis method in addition 
to % variation on periodic basis to estimate the overall 
long term precision for the laboratories which will give 
information similar to that obtained using commercial 
controls.
Accuracy
Since commercially available controls come with manu-
facturer’s range, they give some idea about the accuracy 
of the results. But they may not give the exact informa-
tion about the accuracy as the range is wide as shown 
in Fig. 5 and it is advisable to establish laboratory range 
based on its own mean and standard deviation (SD). It 
Fig. 2 Regression analysis of the CD4+ T cell counts in duplicate analysis method. Regression plots for duplicate analysis method plotted for sam-
ples with normal CD4+ T cell count (a), and low CD4+ T cell counts (b). Day 1 CD4 counts are plotted on X axis and day 2 CD4 counts are plotted on 
Y axis. Data from different laboratories are presented using different colours.
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was not feasible for most of the laboratories using multi-
check controls to establish their own range because of 
their short expiry leading to false estimate of accuracy. 
Establishing provisional range based on 10 measure-
ments and then subsequently using 20 data points for 
establishing the final range [10] would be more appropri-
ate monitoring daily QC in such case.
Duplicate analysis method has also been shown to 
provide information regarding accuracy if tested con-
tinuously [11]. IQC samples showing more than 20% 
variation would indicate inaccuracy in the testing. The 
data for the 6 laboratories that used both the types of 
controls showed average rate of QC failures as 2.3, 0.5, 
and 3 times laboratory-year, respectively, when duplicate 
analysis method, multi-check and IMMUNO-TROL con-
trols were used, for which appropriate corrective actions 
were taken. The duplicate analysis method and the use 
of IMMUNO-TROL controls showed similar QC fail-
ure rates. The lower rate of QC failure with Multi-Check 
could be because of use of wider manufacturer’s range.
EQA performances are known to provide more exact 
information regarding accuracy of the testing [4]. All 
these laboratories had acceptable performance in EQA 
program conducted nationally indicating it would be suf-
ficient to use duplicate analysis method on continuous 
basis if the laboratory is successfully participating in reg-
ular EQA programme.
Trend monitoring
One more advantage of the commercially available con-
trols is their ability to monitor trend or shifts in the 
results, which can give the earliest identification of the 
problems related to changes in reagent lots, technical 
staff, instrument settings, environmental condition, etc. 
[12]. However, since most of the laboratories didn’t estab-
lish their own ranges because of short expiry of multi-
check controls, it was not possible for them to monitor 
the trend as it is not recommended to use manufactur-
er’s range for this purpose. Trend monitoring was done 
by only one laboratory using IMMUNO-TROL control 
Fig. 3 Bland–Altman bias plots for the CD4 values obtained on day 1 and day 2. The figure shows the Bland Altman plots for the duplicate analysis 
method using samples with normal (a) and low (b) CD4 counts. The X axis shows the average between the values obtained on both the days and 
the Y axis shows the differences between the values obtained on the 2 days. The mean differences in CD4 counts, the lower limits of agreement 
(mean −2 SD), and the upper limits of agreement (mean +2 SD) are displayed as horizontal lines.
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which has a longer shelf life. A representative LJ plot for 
the laboratory is shown in Fig. 6 along with the simulta-
neous trend monitoring by duplicate analysis method. 
Trends and shifts in duplicate analysis method were 
monitored by deviations of percent variation around 0%. 
The effective trend monitoring by this method was also 
stressed previously using continuous method of duplicate 
analysis [11]. For trend monitoring across CD4 testing 
laboratories, mean and standard error of daily percent 
variations was calculated and plotted against the days of 
the month as shown in Fig.  7. The graph demonstrates 
that the mean and standard error (SE) of percent varia-
tions across the laboratories also fluctuate around 0  %. 
However, the drawback of duplicate analysis method 
is that it detects changes only between two successive 
runs as against the commercial controls which monitor 
trend over the time. But since all the laboratories imple-
ment QC measures for controlling variations because of 
changes in reagent batches (parallel testing), equipment 
settings (equipment validation and calibration), staff 
(training and competency), environment (temperature 
and environment monitoring), the possible factors lead-
ing to trends or shifts in QC data are additionally con-
trolled. Hence the duplicate analysis might be sufficient 
to monitor the trend if these additional measures are 
implemented. 
Cost implications
Commercially available controls are largely manufac-
tured outside India and have to be imported and are very 
expensive. Additionally they have to be run 20 times for 
establishing their range if they are required to be used 
optimally. The approximate cost of these reagents per 
level per month comes to around 100 US dollar, and if 
Fig. 4 Comparison of % CV, mean percent variation differences and r2 values. % CV (calculated for commercial controls) indicated as closed bars 
and mean percent variation (for duplicate analysis method) indicated as open bars are plotted on left Y axis for laboratories 1, 2, 3, 5, 6, 7 (plotted on 
X axis). r2 values calculated by regression analysis for duplicate analysis method are indicated as line diagram and are plotted on Z axis. Error bars for 
each parameter indicate standard error.
Fig. 5 Manufacturer’s range (MR) versus laboratory established 
ranges (LR) for commercial controls for CD4+ T cells. The ranges 
(mean ± 2 SD) for different lots of the commercial controls available 
in different months are plotted. Y axis represents CD4 counts and X 
axis represents months of the range establishment. Blue bars indicate 
manufacturer’s ranges and purple bars indicate laboratory established 
ranges. The yellow triangle in the middle of each bar indicates mean 
values.
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20 runs are performed for range establishment, the cost 
increases by 2 times as it requires one more tube of the 
controls as well as CD4 testing reagents, which cost 
approximately 5–6 USD per test. In the program settings 
in India it increases by many folds as it includes multiple 
laboratories all over the country. The cost factor would 
Fig. 6 Simultaneous trend monitoring by commercial controls and duplicate analysis. a (normal CD4 count), b (low CD4 count) show representa-
tive graphs for simultaneous trend monitoring by duplicate analysis method and by commercial controls by plotting LJ charts. CD4 counts for 
commercial controls are plotted on left Y axis and % variation as obtained by duplicate analysis method is plotted on right Y axis against the no. of 
days on X axis. Green and red colour lines indicate % variation of samples with normal and low CD4 count, respectively. Black coloured solid line and 
two dotted lines on either side indicate 20% limits of percent variation, respectively. Blue line indicate CD4 counts of IMMUNO-TROL controls with 
blue coloured solid line and two dotted lines on either side indicating mean and 2 SD, respectively.
Fig. 7 Trend monitoring by duplicate analysis. Fluctuation of daily % variations for monitoring the trend by duplicate analysis method. Mean and 
SE of % variation of CD4 testing is plotted on Y axis and no. of days are plotted on X axis. % variation for samples with normal CD4 count is shown in 
green colour and that with low CD4 counts is shown in red colour.
Page 8 of 9Shete et al. AIDS Res Ther  (2015) 12:25 
become more important in case of decentralization of 
the care as along with the increase in number of centers, 
the sample load per center would decrease drastically. In 
duplicate analysis method, all this cost gets nullified mak-
ing it a cheaper method for broader use.
Conclusion
Although commercially available controls are recom-
mended for monitoring of daily QC, they have some limi-
tations such as altered sample displays, requirement of 
laboratory established range for optimal use and factors 
affecting establishment of laboratory range, etc. Also cost 
of running these controls is very high, which may not be 
affordable in resource limited settings. Contrary, dupli-
cate analysis method using previous day samples can 
monitor QC at no extra cost and may be financially via-
ble alternative, especially in the primary and secondary 
care settings. The analysis showed that it has a potential 
to monitor daily as well as long term precision, accuracy 
as well as trends if done appropriately and continuously. 
This QC method along with the successful participation 
in EQAS and institution of other QC measures for con-
trolling variations caused by reagent, equipment, staff 
and environment would serve as the cost effective system 
for monitoring quality of CD4 count testing.
Methods
QC data from 11 laboratories from different regions in 
India under NACO ART program was collected for anal-
ysis during the period of Jan to Dec 2013. CD4 estimating 
equipments used in these laboratories were FACSCali-
bur (n  =  5), FACSCount (n  =  3) (both from Becton–
Dickinson, USA) and Cyflow (Partec, Germany) (n = 3) 
as shown in Table 1. All the laboratories used duplicate 
analysis method (previous days sample) for daily CD4 
QC monitoring. Six of 11 laboratories also used com-
mercially available controls either in addition to or as a 
substitute to duplicate analysis method for daily QC for 
variable period ranging from 1 month to entire year. All 
laboratories performed the procedures as per SOPs and 
manuals respective to their available equipment. All 11 
laboratories successfully participated in the national 
external quality assurance (EQA) programme for CD4 
count estimation for last four years.
Duplicate analysis
In this method, two whole blood samples collected and 
processed on previous day having low (200–400 cells/
ml) and normal CD4 (>500 cells/ml) count were used 
for the daily internal quality control. The samples were 
stored at room temperature for processing on FAC-
Scount/FACSCalibur and at 2–8°C for Cyflow as per 
the manufacturer’s instructions. The CD4 values were 
compared with the previous day values and percent 
variation between the values was calculated by using fol-
lowing formula: observed (day 2 value)/expected (day 1 
value)  ×  100  −  100. Percent variation more than ±20 
was considered as non acceptable [7].
Commercially available stabilized controls
Commercially available controls used by the laborato-
ries were IMMUNO-TROL (Beckman coulter, USA) or 
Multi-Check (BD biosciences, USA). The controls were 
stored at 2–8°C as per the manufacturer’s instructions 
and processed along with the samples as per the SOPs 
to ensure their values were within the prescribed ranges. 
Most of the laboratories using multi-check controls used 
manufacturer’s range for monitoring the daily QC as the 
controls had shorter shelf life of about 1 month and it was 
not feasible to establish laboratory range for them. For 
IMMUNO-TROL controls, laboratory established ranges 
were used after performing 20 runs. LJ charts were plot-
ted daily on the basis of laboratory established ranges for 
monitoring precision, biases and trends as per the West-
gard rules. % CV was calculated at the end of the month 
for both the commercial controls.
Data collection and analysis
The QC data as well as representative displays of the pro-
cessed samples obtained from each of the equipments 
(FACSCalibur, FACSCount and Cyflow) from the labo-
ratories were collected over the last year for analysis and 
comparison. Results of QC using commercially available 
controls and using duplicate analysis method were ana-
lysed with respect to equipment displays of the processed 
samples and for precision, accuracy and trend monitor-
ing. The precision, accuracy and trend was monitored by 
calculating % CV, out of range readings based on manu-
facturer or laboratory established ranges and by plotting 
LJ charts, respectively, in case of commercial controls.
The precision in case of duplicate analysis method 
was monitored by mean percent variation and r2 values 
for assessing long term precision in addition to the daily 
percent variations. The mean of daily percent variations 
was calculated after ignoring minus (−) sign of percent 
variation over a period of months. The correlations of the 
CD4 counts on both the days were analyzed by Pearson’s 
correlation test and regression analysis for calculating 
r2 values. The degree of agreement between the values 
obtained on 2 days and the biases were estimated using 
Bland–Altman analysis. Percent variations beyond 20% 
were unacceptable and considered as QC failure. Rate of 
QC failures per laboratory-year was calculated by divid-
ing number of QC failures (percent variation >20% for 
duplicate analysis method or out of range readings for 
commercial controls) in all laboratories by sum of total 
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months contributed by all laboratories. Mean and stand-
ard error (SE) of daily percent variations from CD4 test-
ing laboratories was calculated and plotted against days 
for trend monitoring by duplicate analysis method. 
Microsoft Excel, GraphPad prism (version 5) and Sigma-
Plot (version 12.0) software were used for statistical anal-
ysis and plotting graphs.
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